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The mineral and bone disorder of chronic kidney disease
remains a challenging complication in pediatric end-stage
renal disease. Here, we assessed symptoms, risk factors and
management of this disorder in 890 children and adolescents
from 24 countries reported to the International Pediatric
Peritoneal Dialysis Network Registry. Signs of this disease
were most common in North American patients. The
prevalence of hyperphosphatemia increased with age from
6% in young infants to 81% in adolescents. Serum
parathyroid hormone (PTH) was outside the guideline targets
in the majority of patients and associated with low calcium,
high phosphorus, acidosis, dialysis vintage and female
gender. Serum calcium was associated with dialytic calcium
exposure, serum phosphorus with low residual renal function
and pubertal status. PTH levels were highest in Latin America
and lowest in Europe. Vitamin D and its active analogs were
most frequently administered in Europe; calcium-free
phosphate binders and cinacalcet in North America. Clinical
and radiological symptoms markedly increased when PTH
exceeded 300pg/ml, the risk of hypercalcemia increased with
levels below 100pg/ml, and time-averaged PTH
concentrations above 500pg/ml were associated with
impaired longitudinal growth. Hence, the symptoms and
management of the mineral and bone disorder of chronic
kidney disease in children on peritoneal dialysis showed
substantial regional variation. Our findings support a PTH
target range of 100–300pg/ml in the pediatric age group.
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The management of the mineral and bone disorder (MBD)
associated with chronic kidney disease (CKD–MBD) is
particularly challenging in children and adolescents with
end-stage renal disease (ESRD), in whom treatment efforts
not only need to prevent debilitating musculoskeletal
morbidity but also must be compatible with statural growth
and, in view of a potentially long lifespan, consider
preservation of long-term cardiovascular health. In this
context, the optimal target concentration ranges of para-
thyroid hormone (PTH) and mineral electrolytes allowing
appropriate bone turnover and avoiding extraosseous
calcifications are a focus of attention. Current pediatric
consensus guidelines recommending permissive mild-to-
moderate hyperparathyroidism (HPT) and maintenance of
low normal serum calcium (Ca) and normal inorganic
phosphorus (Pi) levels operate on a limited evidence base.1,2,3
Recently, the International Pediatric Peritoneal Dialysis
Network (IPPN) established a prospective clinical registry
collecting detailed clinical and biochemical information in
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children receiving chronic peritoneal dialysis (PD) around the
globe. It is hoped that this internet-based registry will overcome
the problem of small numbers in pediatric ESRD research and
provide the critical mass necessary to identify risk factors and
surrogate markers for various clinical outcomes, test the validity
of current clinical practice guidelines and provide a database for
the development of new guidelines. In this study, we provide
an in-depth analysis of the clinical features, determinants and
treatment of CKD–MBD, assess compliance with international
pediatric CKD–MBD guidelines and attempt to define a rational
PTH target range for children receiving chronic PD.
RESULTS
Signs and symptoms of CKD–MBD
Clinical symptoms and/or radiological signs of bone disease
were observed in 139 of the 890 patients at registry entry
(15%). These included (more than one item per patient
permitted) radiological signs of osteodystrophy/rickets
(9.4%), radiological osteopenia (4.5%), limb deformities
(5%) and current bone pain (1.4%). Eight additional patients
(0.9%) had syndromal osteodysplasias. Tissue calcifications were
reported in 14 patients (1.5%). Serum biochemistry according
to signs and symptoms of bone disease is given in Table 1.
Among 271 patients followed for 12 months, signs and
symptoms of CKD–MBD persisted in 20 (7.4%), resolved in
32 (11.8%) and developed de novo in 17 (6.3%). Their
biochemical and treatment characteristics are given in Table 2.
Biochemical profile
Biochemistry statistics for the total population are given in
Table 1. Mean serum PTH was slightly higher in girls (n¼ 401;
median 277, interquartile range 144–550 pg/ml) than in boys
(n¼ 489; 246, 121–486 pg/ml, P¼ 0.05), whereas serum Ca and
Pi levels did not differ between sexes. Serum Pi was higher in
171 post-pubertal (1.85±0.47 mmol/l) than in 719 pre- and
early pubertal patients (1.72±0.40 mmol/l, Po0.0005).
The 447 oligoanuric patients (daily urine outputo300 ml/m2)
had significantly higher serum Ca (2.40±0.24 versus 2.35±
0.23 mmol/l, Po0.01) and serum Pi (1.79±0.42 versus 1.69±
0.37 mmol/l, Po0.0001) than patients with greater residual
diuresis, whereas urine output did not affect serum PTH.
The biochemical profile is stratified by PD modality in
Table 3. Mean serum Ca was lower with continuous
ambulatory PD than on automated PD; this was associated
with significantly lower dialysate Ca exposure resulting from
lower daily PD fluid turnover and a lower proportion of
solutions with supraphysiological dialysate Ca content.
A univariate correlation matrix of factors associated
with mean serum PTH and mineral electrolytes is given in
Table 4. By categorical analysis, patients with time-averaged
PTH o100 pg/ml showed a 23.8% prevalence of hyper-
calcemia (mean serum Ca42.7 mmol/l at age o1 year,
42.57 mmol/l at 1–6 years and 42.55 mmol/l at age 46
years1), as compared with 10–15% in patients with mean
PTH ranging 100–200, 200–300, 300–500 and 4500 pg/ml
(Po0.0001).
Stepwise multiple linear and logistic regression analyses were
performed to identify the independent predictors of PTH, Ca
and Pi, factoring in age, gender, dialysis vintage, biochemical
variables, residual renal function, dialysis modalities and
exposure to the medications. Log-transformed mean PTH
concentrations were independently predicted by mean serum
Ca (regression coefficient ß:0.772, partial R2: 0.03, Po0.0001),
serum Pi (ß: 0.348, partial R2: 0.019, Po0.0001), serum
bicarbonate (ß: 0.026, partial R2: 0.007, P¼ 0.009), time on
dialysis (ß: 0.035, partial R2: 0.012, P¼ 0.01) and female sex
(ß: 0.18, partial R2: 0.008, P¼ 0.008).
The risk of a having a mean serum PTH concentration
4300 pg/ml was independently increased by higher serum Pi
(for unit 0.1 mmol/l: odds ratio (OR) 1.06, 95% confidence
interval (CI) 1.02–1.1, Po0.01) and longer duration of
dialysis (for unit years: OR 1.11, CI 1.00–1.20, Po0.05), and
reduced by higher mean serum Ca (for unit 0.1 mmol/l: OR
0.83, CI 0.83–0.95, Po0.01), the use of supraphysiological
dialysate Ca concentrations (OR 0.55, CI 0.40–0.76,
Po0.0005) and higher serum bicarbonate levels (for unit
mmol/l: OR 0.94, CI 0.90–0.99, Po0.02).
Mean serum Ca concentrations were predicted by dialysate
Ca exposure (ß: 0.06, partial R2: 0.024, Po0.0001), patient
age (ß: 0.047, partial R2: 0.017, P¼ 0.0005), and serum
bicarbonate (ß: 0.055, partial R2: 0.007, P¼ 0.02). Mean
serum Pi levels were affected by residual diuresis (ß: 0.867,
partial R2: 0.023, Po0.0001) and pubertal status (ß: 0.292,
partial R2: 0.008, Po0.01).
Figure 1 depicts the percentage of mean laboratory values
of Ca, P and PTH within, below and above the range
Table 1 | Serum biochemistry in pediatric patients with
clinical and/or radiological signs of CKD–MBD at first
observation
N PTH (pg/ml) Ca (mmol/l) Pi (mmol/l)
All patients 890 257 (126–523) 2.37±0.24 1.75±0.41
Bone pain
Yes 13 488 (423–1495)**** 2.39±0.15 2.1±0.47***
No 877 255 (121–520) 2.37±0.24 1.74±0.47
Bone deformities
Yes 45 378 (178–1020)** 2.39±0.22 1.79±0.45
No 845 243 (124–510) 2.37±0.24 1.74±0.41
Tissue calcification
Yes 14 248 (160–582) 2.50±0.30 2.11±0.7*
No 876 257 (125–523) 2.48±0.24 1.75±0.5
Radiological osteodystrophy
Yes 84 492 (214–964)**** 2.38±0.34 1.93±0.5***
No 806 245 (120–455) 2.37±0.23 1.73±0.40
Radiological osteopenia
Yes 40 275 (158–529)* 2.46±0.23* 1.86±0.4*
No 850 256 (125–519) 2.37±0.24 1.75±0.5
Abbreviations: CKD, chronic kidney disease; MBD, mineral and bone disorder; Pi,
inorganic phosphorus; PTH, parathyroid hormone.
Data are median (interquartile range) for PTH, mean±s.d. for other parameters.
*Po0.05, **Po0.01, ***Po0.001, ****Po0.0005.
1296 Kidney International (2010) 78, 1295–1304
or ig ina l a r t i c l e D Borzych et al.: CKD–MBD in pediatric PD
recommended in the Kidney Disease Outcomes Quality
Initiative (KDOQI) and PTH values according to Kidney
Disease: Improvement of Global Outcome (KDIGO) guide-
lines for the different pediatric age groups. The proportion
of patients with elevated serum Pi was higher in adolescents
(Pi: Po0.0001).
Pharmacological treatment of CKD–MBD
The distribution of medications administered to control
mineral metabolism and HPT is listed by age group in
Table 5. Treatment with calcium-free and calcium-containing
phosphate binders, 25OH-vitamim D3 and active vitamin D
analogs did not affect serum Ca and Pi levels. However, mean
PTH levels were significantly higher in patients receiving
active vitamin D analogs (median 325, interquartile range
155–598 pg/ml) than in untreated patients (median 167,
interquartile range 94–301 pg/ml, Po0.0001). Of the 356
patients with mean PTH levels below 200 pg/ml, 127 (36%)
received no active vitamin D analogs throughout follow-up.
Prediction of CKD–MBD by PTH
The data available in this study was used to identify the range
of PTH associated with the lowest likelihood of complica-
tions of CKD–MBD. These were defined (a) in the total
cohort by the presence of radiological signs of uremic
osteodystrophy and/or osteopenia, bone pain, limb defor-
mities or extraosseous calcifications at any time during the
observation period, and (b) in the 271 patients followed
prospectively for 12 months by the persistence or de novo
development of signs and symptoms of CKD–MBD.
The rate of patients with CKD–MBD complications at any
time was significantly increased when mean PTH levels
exceeded 300 pg/ml (Figure 2). Various PTH target ranges
were tested by receiver operating characteristic analysis with
Table 2 | Biochemical and treatment characteristics of 271 patients followed prospectively for 12 months, in whom CKD–MBD
signs and symptoms persisted, developed de novo, resolved or remained absent
Persistent De novo Resolved Absent
N 20 17 32 202
Serum PTH (pg/ml) 411 (290–591)ab 577 (290–733)a 275 (162–488)b 269 (159–443)b
Serum Ca (mmol/l) 2.46±0.24 2.36±0.24 2.39±0.16 2.40±0.17
Serum Pi (mmol/l) 1.73±0.38 1.68±0.49 1.78±0.36 1.72±.28
% Time on vitamin D 58±45a 20±36b 33±41b 25±35b
% Time on active vitamin D analogue 90±19 87±20 89±20 74±31
% Time on Ca-containing phosphate binder 59±45a 52±44a 85±28b 86±30b
% Time on Ca-free phosphate binder 28±45ab 41±51a 32±41ab 13±27ab
% Time on cinacalcet 0a 7.3±1.8b 3.1±1.3ab 0.9±0.7a
Abbreviations: CKD, chronic kidney disease; MBD, mineral and bone disorder; Pi, inorganic phosphorus; PTH, parathyroid hormone.
Drug treatment is given as the fractional observation time spent on treatment. Numbers are mean±s.d. for normally distributed, and median (interquartile range) for skewed
parameters. Different superscript letters within a row denote significant differences between groups.
Table 3 | Dialytic calcium exposure and mineral metabolism by PD modality
CAPD NIPD CCPD
N 232 318 320
Residual urine volume (ml per m2 per day) 670 (100–1250)a 640 (100–1100)a 140 (0–540)b
Daily PD fluid turnover (l per m2 per day) 4.47±1.95a 7.53±6.90b 8.27±6.78b
Dialysate calcium (mmol/l) 1.32±0.18a 1.36±0.22a 1.43±0.25b
Dialysate calcium exposure (mmol per m2 per day) 6.12±3.24a 9.30±4.86b 11.0±4.54c
Serum PTH (pg/ml) 256 (128–538) 272 (135–575) 259 (125–492)
Serum Ca (mmol/l) 2.34±0.21a 2.38±0.25b 2.39±0.26b
Serum Pi (mmol/l) 1.71±0.39 1.73±0.38 1.78±0.45
Abbreviations: CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cycling peritoneal dialysis; NIPD, nocturnal intermittent peritoneal dialysis; PD, peritoneal
dialysis; Pi, inorganic phosphorus; PTH, parathyroid hormone.
Numbers are mean±s.d. for normally distributed, and median (interquartile range) for skewed parameters. Different superscript letters within a row denote significant
differences between groups. Twenty patients with ‘other’ PD modality were excluded from this analysis.
Table 4 | Factors correlated with PTH and mineral electrolyte
profile
PTH Ca Pi
Age 0.10** 0.08*
PD duration 0.17****
Serum Ca 0.19****
Serum Pi 0.13***
Serum bicarbonate 0.11*** 0.18**** 0.09**
Mean urine volume 0.09** 0.15****
Dialysate Ca exposure 0.15**** 0.10***
Urinary creatinine clearance 0.22****
Dialytic creatinine clearance 0.13** 0.11*
Total creatinine clearance 0.17*** 0.17***
Active vitamin D analogue 0.30****
Oral calcium (suppl./binders) 0.10**
Abbreviations: PD, peritoneal dialysis; Pi, inorganic phosphorus; PTH, parathyroid
hormone; suppl., supplements.
Values are Spearman’s correlation coefficients, asterisks indicate significance level
(****Po0.0001, ***Po0.001, **Po0.01, *Po0.05). Intra-patient mean values were
calculated from all available data points in this mixed longitudinal study. For
medications, fractional time of drug exposure (never=0, throughout observation=1)
was used for correlation analysis. Data pairs were available from 890 patients for all
parameters except residual and dialytic creatinine clearance (available in 411
patients).
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systematic variation of upper and lower cutoff values of mean
PTH. The optimal PTH target range was 10–300 pg/ml (area
0.625±0.019), which predicted the absence of CKD–MBD
complications with 60.4% sensitivity and 64.6% specificity.
The 200–300 pg/ml target recommended by KDOQI
(0.527±0.013, Po0.0001) and the two- to threefold upper
limit of normal target suggested by the European Pediatric
Dialysis Working Group (EPDWG) (area 0.536±0.012,
Po0.0001) were of inferior predictive value, as they excluded
many asymptomatic patients, resulting in greater reduction
in sensitivity (16.5 and 15.2%) than gain in specificity (88.9
and 91.9%). The KDIGO target range of two- to ninefold the
upper normal limit also showed inferior predictive perfor-
mance (area 0.575±0.012, Po0.05), mainly because of the
lower specificity (48.4%) as it encompassed many patients
with active CKD–MBD.
Likewise, in the longitudinal analysis the resolution or
persistent absence of CKD–MBD signs and symptoms was
better predicted by time-averaged PTH between 10 and
300 pg/ml (area 0.632±0.041, sensitivity 53.4%, specificity
73%) than by the KDOQI (area 0.506±0.033, Po0.0001,
sensitivity 17.5%, specificity 83.8%) and EPDWG target
ranges (area 0.564±0.011, P¼ 0.08, sensitivity 12.8%,
specificity 100%), whereas the KDIGO target range was of
equivalent overall predictive usefulness (area 0.610±0.044,
non-significant) as a result of higher sensitivity (67.9%) and
lower specificity (54.1%).
Regional variation of CKD–MBD
Clinical or radiological bone disease showed significant
regional variation (Po0.0001), being reported most
frequently in North America (39%) and least commonly in
Asia (7.5%). The biochemical profiles and medications
according to regions are given in Table 6, and median
time-integrated PTH levels by country in Figure 3. PTH levels
were highest in Latin American countries and in the United
States and lowest in European children, with reciprocal
differences in serum Ca. The PTH variation among regions
remained highly significant (Po0.0001) even when control-
ling for patient age and sex, PD duration and serum Ca, Pi
and bicarbonate levels. Serum Pi levels were highest in North
American and lowest in Latin American patients. The
significant regional variation of serum Pi persisted when
correcting for residual diuresis and pubertal status, PD
modality and the use of phosphate binders (Po0.001).
CKD–MBD and longitudinal growth
The analysis of statural growth was restricted to 214 pre- and
early pubertal patients (Tanner stages 1–3) with at least 12
months of longitudinal follow-up. Mean height standard
deviation score (SDS) at first observation was 2.43±1.64;
height was below the third percentile in 39% of children. The
annual prospective change in height SDS (mean: 0.03±1.1
per year) tended to be inversely correlated with the mean
plasma PTH levels (r¼0.11, P¼ 0.08) (Figure 4). Patients
with mean PTH 4500 ng/ml exhibited a significant loss in
height SDS (0.28±0.52 SDS per year) as compared with
children with lower PTH levels (0.05±0.71; Po0.05) The
inverse correlation between change in height SDS and mean
PTH became more consistent with longer follow-up, and was
highly significant in the 93 children observed for at least 18
months (r¼0,28, P¼ 0.005).
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Figure 1 | Fractional distribution of patients with mean serum Ca, inorganic phosphorus, intact parathyroid hormone (iPTH)
within (vertical lines), below (undulating lines) and above (dotted) target values as recommended by Kidney Disease Outcomes
Quality Initiative (KDOQI), and mean serum PTH as recommended by Kidney Disease: Improvement of Global Outcome (KDIGO)
Guidelines.
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In a logistic regression analysis, the likelihood of catch-up
growth (defined by a positive change in height SDS)
independently increased with growth hormone therapy (OR
7.21; CI 2.53–20.6, P¼ 0.0002), preserved residual diuresis
4300 ml per m2 per day (OR 3.25; CI 1.66–6.31, P¼ 0.0006)
and patient age (OR 1.07; CI 1.1.0–1.14, P¼ 0.04), and
decreased with higher baseline height SDS (OR 0.72; CI
0.59–0.88, P¼ 0.001) and, with borderline significance, with
higher mean PTH levels (OR for unit 100 pg/ml: 0.90; CI
0.80–1.01, P¼ 0.07). The likelihood of catch-up growth was
independent of gender or duration of ESRD.
An analysis of covariance was performed to further
explore a potential interaction of PTH levels with growth
hormone therapy. Whereas, patients receiving growth
hormone generally showed more positive height SDS changes
than untreated patients, the slopes of the association of PTH
with change in height SDS did not differ significantly
between children with and without growth hormone therapy
(P¼ 0.88), indicating that growth hormone promoted
growth independent of the prevailing serum PTH level.
DISCUSSION
This study demonstrates that CKD–MBD remains a significant
problem in children on chronic dialysis. On a global scale, at
least one in six children shows radiological and/or clinical signs
of bone disease and 44% exhibit severe secondary HPT with
PTH levels exceeding five times the upper limit of normal.
At the other end of the bone disease spectrum, 4.5% of patients
showed isolated radiological osteopenia with higher serum
calcium and lower PTH levels, compatible with a state of low
bone turnover. All these conditions were associated with an
elevated serum Ca*Pi product, compatible with the notion that
both types of uremic bone-mineral disorder may increase the
risk of extraosseous calcification.4
The analysis of the mineral biochemistry profiles revealed
several interesting associations. Higher serum calcium levels
were independently associated with younger patient age,
probably reflecting the higher physiological range of serum
calcium in infants. Dialytic Ca exposure was an additional
independent positive predictor of serum Ca. Continuous
Table 5 | Pharmacological treatment of CKD–MBD in pediatric
CPD patients stratified by age
o1
year
1–5
years
6–11
years
412
years All
N 67 184 291 348 890
Phosphate binders (any) 61.2% 82.7% 89.7% 95.7% 88.3%
Calcium carbonate/acetate 53.7% 71.7% 71.5% 67.8% 68.8%
Sevelamer 4.5% 2.7% 7.2% 10.6% 7.4%
Calcium carbonate
acetate+sevelamer
3% 8.2% 11% 16.4% 11.8%
Lanthanum carbonate 0% 0% 0% 0.8% 0.3%
25-OH-vitamin D3 29.8% 30.2% 22.3% 23.3% 24.9%
Active vitamin D analogue (any) 58.2% 81.4% 71.5% 76.4% 74.5%
Calcitriol 26.9% 48.9% 47.1% 51.9% 47.8%
1a-calcidiol 31.3% 31.9% 22.7% 22.8% 25.3%
Paricalcitol 0% 0.6% 1% 1.7% 1.1%
Doxercalciferol 0% 0% 0.7% 0% 0.2%
Cinacalcet 0% 0% 1.4% 6.1% 2.8%
Abbreviations: CPD, chronic peritoneal dialysis; CKD, chronic kidney disease; MBD,
mineral and bone disorder.
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Figure 2 |Percentage of patients with alterations of bone and
mineral metabolism (bone pain, limb deformities, extraosseous
calcifications, radiological osteomalacia and/or osteopenia)
stratified by time-averaged mean parathyroid hormone (PTH)
levels. Groups sharing same letters do not differ significantly.
Table 6 | Regional variation of mineral metabolism
Latin America North America Europe Turkey Asia
N 201 129 324 142 94
Serum Ca (mmol/l) 2.33±0.24a 2.39±0.30ab 2.41±0.23b 2.33±0.21a 2.37±0.19ab
Serum Pi (mmol/l) 1.66±0.35a 1.91±0.55b 1.71±0.36ac 1.79±0.41c 1.77±0.43ac
Serum PTH (pg/ml) 418 (245–733)a 290 (163–627)a 175 (87–377)b 297 (152–548)a 208 (121–331)b
PD fluid Ca2+ concentration 1.27±0.12a 1.49±0.28b 1.41±0.23c 1.31±0.16a 1.42±0.27c
Dialysis modalities (%) CAPD/APD/CCPD/other 32/51/16/1 4/16/79/1 13/46/39/2 60/20/19/1 38/19/33/10
Ca-containing phosphate binders 91.4%a 57.8%b 76.9%c 87.0%a 89.4%a
Ca-free phosphate binders 3.1%a 45.5%b 28.1%c 7.1%a 32.2%c
25-OH-vitamin D3 26.0%
ab 18.6%bc 35.6%a 10.2%c 32.8%a
Active vitamin D analogues 72.0%ab 74.8%ab 81.6%a 66.6%b 67.3%b
Cinacalcet 0.5%a 9.6%b 2.4%a 0.7%a 2.0%a
Abbreviations: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cycling peritoneal dialysis; Pi, inorganic phosphorus;
PTH, parathyroid hormone.
Numbers are median (interquartile range) for PTH and mean±s.d. for other parameters. Different superscript letters within a row denote significant differences between
groups (Po0.05).
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cycling PD patients were exposed to higher amounts of PD
fluid with a higher average Ca concentration than children
undergoing continuous ambulatory PD, resulting in a
considerably higher dialysate-plasma Ca2þ gradient and,
consequently, higher serum Ca levels. Surprisingly, the use of
calcium containing phosphate binders and active vitamin D
analogs was not predictive of serum Ca. We speculate that the
avoidance of these drugs in patients prone to hypercalcemia
and their preferential administration in hypocalcemic patients
concealed their calcemic properties in the cohort analysis.
Mean serum Ca and Pi were significantly higher in
oligoanuric patients. Residual urine volume was the strongest
independent predictor of the risk of developing an elevated
Ca*Pi product, indicating a crucial role of residual renal
function for mineral electrolyte homeostasis in children
receiving chronic PD.
Hyperphosphatemia was more common in adolescents
despite higher phosphate binder prescription, likely reflecting
poor medication adherence during puberty, a period of
changing food preferences and increased psychological and
social stress leading to rejection of disease-related restrictions.
Of particular interest in this global study is the significant
regional variation in mineral metabolism control. Serum Pi
levels were highest in North American and lowest in Latin
American patients. As these differences were independent of
residual renal function, pubertal status, PD modality and
phosphate binder prescription, regional diversity in nutri-
tional phosphorus intake related to cultural preferences and
patient adherence with nutritional advice may be the most
likely explanation of the observed differences.
The main determinants of plasma PTH were serum Ca, Pi
and bicarbonate levels as well as dialysis vintage. The risk of
mean PTH exceeding 300 pg/ml increased by 12% per
0.1 mmol/l decrease in Ca, by 5% per 0.1 mmol/l increase
in Pi and by 5% per 0.1 mmol/l decrease in bicarbonate.
These findings re-emphasize the importance of serum Ca in
PTH control. Even low normal Ca, as recommended in the
pediatric KDOQI guidelines, may increase the risk of
developing severe HPT. The use of Ca-containing phosphate
binders was not correlated with mean PTH levels and the
administration of active vitamin D analogs even showed a
positive relationship, reflecting physicians’ responses to
patients’ therapeutic demands. Notably, the calcium content
of the PD fluid, probably the most steady determinant of
calcium balance in chronic PD patients, was an independent
negative predictor of PTH, suggesting effective modulation of
PTH levels by fluid calcium content.
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patients receiving recombinant growth hormone. SDS, standard
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The consistent inverse relationship of PTH with serum
bicarbonate levels is in keeping with observational and
preliminary interventional study evidence in adult patients
supporting a direct stimulatory effect of acidosis on PTH
secretion.5–7 It has been proposed that acidosis may reduce
the sensitivity of the Ca sensing receptor to circulating Ca by
inducing conformational alterations in the Ca-binding sites.8
Female gender was another cofactor predisposing to
more marked HPT. This observation is in line with the
threefold higher prevalence of primary HPT in women,9 the
reduced PTH suppressibility and faster progression to para-
thyroid nodular hyperplasia in female hemodialysis patients,
and the diminished antiproliferative efficacy of calcitriol
on explanted female parathyroid tissue.10–12 Although this
gender difference has been related to a direct stimulatory
action of estrogen on the parathyroid,13 we observed higher
PTH levels across all age groups independent of pubertal
status consistent with an intrinsic gender dimorphism in
parathyroid function.
In addition to and independent of all these factors, severe
HPT occurred with a 10% higher likelihood with each year on
dialysis, compatible with gradual development of parathyroid
gland autonomy over time.
Two specific pediatric CKD–MBD guidelines have been
released, one by KDOQI and the other by the EPDWG.1,2
Recently, KDIGO released CKD–MBD recommendations
applicable to both adults and children.3 These guidelines
markedly differ with respect to the recommended PTH target
range: whereas the KDOQI document recommended to
maintain concentrations at 200–300 pg/ml, the EPDWG
proposed two to three times the upper limit of the normal
range (that is, approximately 120–180 pg/ml) and the recent
KDIGO guideline defines a range between two and nine
times the upper limit of normal (that is, approximately
120–500 pg/ml) as acceptable. This survey demonstrates that
adherence to the PTH guideline targets remains an elusive
goal, with 59% of children exceeding the upper limit of the
EPDWG, 44% that of the KDOQI, and 20% that of the
KDIGO target range. In addition, a sizable fraction exhibited
PTH levels below the lower end of the target ranges, resulting
in o1 in six patients maintaining PTH within the KDOQI
target. The comparison of PTH levels by country disclosed
remarkable regional differences, with three- to fivefold higher
mean levels in the Latin American countries and the United
States as compared with most of the European countries. The
PTH variation mirrored in part reciprocal differences in
serum Ca but remained highly significant after correction for
Ca, and persisted when additionally accounting for Pi and
bicarbonate levels, age, gender and dialysis vintage. Hence,
the regional differences in PTH control might primarily
reflect divergent therapeutic policies. Indeed, the median
PTH level in the European centers matched the European
guidelines, whereas the PTH median value in the North
American centers was well within the target range of the
KDOQI guidelines. The prescription of vitamin D and active
vitamin D analogs was highest in the European centers,
possibly reflecting a lower threshold of using these drugs to
suppress PTH to the lower target range preferred in Europe.
The optimal PTH target for children is a matter of
long-standing controversy. Bone histopathology studies,
considered gold standard in assessing CKD–MBD, have been
performed in limited numbers of pediatric patients with
partially conflicting results.14–17 Whereas markedly elevated
PTH levels are associated with osteitis fibrosa, a possible
correlation of normal or mildly elevated PTH with low
turnover bone disease appears less clear.
The detailed clinical information collected in the registry
allowed us to address the relationship of serum PTH with
signs and symptoms of bone disease. The prevalence,
persistence and de novo development of clinical and/or
radiological CKD–MBD were clearly associated with exposure
to PTH levels exceeding 300 pg/ml. A receiver operating
characteristic analysis comparing the power of different PTH
ranges to predict the absence of CKD–MBD related morbidity
supported an acceptable limit of 10–300 pg/ml. This range
includes symptom-free patients with superior sensitivity than
the narrower KDOQI and EPDWG targets, and better
specificity than the KDIGO target range, which tends to
include a sizable fraction of symptomatic patients with PTH
between 300–500 pg/ml.
Longitudinal growth, a treatment end point peculiar to
the pediatric population, is a potential indirect surrogate
marker of bone health. Weak positive correlations between
PTH levels and growth rates were found in some but not
confirmed by other studies of children with CKD and on
dialysis.18–22 In addition, growth rates did not differ between
children with low bone turnover and other histomorpho-
metric phenotypes.17 Overcoming the size limitations and
potential selection bias of previous studies, our longitudinal
analysis of 4200 pre- and early pubertal children disclosed a
slight negative association of relative growth with PTH
exceeding 500 pg/ml, which was independent of residual renal
function and growth hormone therapy, the main covariates
of statural growth in this population. Our analysis provides
factual evidence that low PTH levels are not associated with
impaired statural growth.
Although the analysis of clinical and radiological bone
disease and statural growth provides an idea about the
acceptable upper limit of the PTH target range in children,
serum calcium levels over time were available as a surrogate
marker of potential low bone turnover. The fraction of
patients with consistent hypercalcemia increased with PTH
levels below 100 pg/ml, providing a rationale to use this level
as a lower target limit. In this context, it is worth mentioning
that many children on chronic PD retain PTH concentrations
between 100 and 200 pg/ml without hypercalcemia or
osteopenia and with good longitudinal growth. More than
a third of the children with mean PTH o200 pg/ml did not
receive any active vitamin D analogue treatment.
In conclusion, this analysis of a global pediatric ESRD cohort
highlights the wide variability of CKD–MBD and identifies
residual renal function, dialysis vintage, gender, pubertal status,
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serum bicarbonate and dialysate calcium content as impor-
tant determinants of mineral metabolism and PTH control.
We observed major regional variation in the manifestations
and management of pediatric CKD–MBD. Although morbidity
from CKD–MBD clearly increased with PTH levels 4300 pg/ml,
the PTH–calcium relationship indicates 100 pg/ml as a reason-
able lower target limit. We recognize the limitations of this
registry-based analysis, which lacks sensitive information on
bone and vascular morphology and function and conclusive
long-term end points, such as late fracture and cardiovascular
event rates. It is hoped that the IPPN will contribute to the
generation of such prospective information as it continues to
follow children with ESRD around the globe.
MATERIALS AND METHODS
Data collection
The IPPN registry collects information from children and
adolescents treated with chronic PD in 75 pediatric dialysis centers
in 27 countries around the globe. All prevalent and incident
consenting patients in each participating center are enrolled and
followed until discontinuation of PD. Because of the voluntary
character of the registry, the nationwide coverage of pediatric PD
patients varies between countries (for example, US 11%; Turkey
19%; 12 European countries 31%; Canada 59%; Chile, Korea,
Argentina, Singapore, Nicaragua: 80–100%). Data input to the IPPN
registry is performed exclusively via an Internet-based web platform
(http://www.pedpd.org). Data pertaining to basic patient and PD
modality characteristics, growth and weight gain, serum biochem-
istry results, complications associated with the uremic state and
dialysis, PD-related and other infections, hospitalizations, and
information about pharmacological treatment are submitted every
6 months. The data is automatically checked for accuracy and
completeness. In addition, center-specific demographic data and PD
practices are collected at the time of center registration. Data
protection is ensured by pseudonymized data input.
The registry protocol was approved by the ethical committees/
institutional review boards as required at each participating center.
Written parental consent and, whenever appropriate, assent from
patients is obtained.
Patients
Between April 2007 and June 2009, data on 890 prevalent pediatric
patients receiving chronic PD followed in 61 centers in 24 countries
in Europe, the Americas and Asia were reported to the IPPN registry
(see Appendix). Patients were aged 1 month to 19.9 (median 10.3)
years at time of enrollment. The underlying kidney disorders
included renal hypodyspasia with or without obstructive or refluxive
uropathy (42.3%), steroid-resistant nephrotic syndrome (19.1%),
other glomerulopathies (8.3%), hemolytic uremic syndrome (6.2%),
nephronophthisis (5.4%), polycystic kidney disease (4.9%), systemic
vasculitis (3.8%), post-ischemic renal disease (2.5%), metabolic
disease (2.3%) and others/unknown (5.2%).
Mean duration of ESRD at the time of enrollment was 2.4±2.5
years and PD vintage 1.9±1.7 (0.1–11.8) years. In all, 11% of patients
were enrolled within 3 months of PD initiation. At 6-, 12-, 18-, and 24-
month follow-ups, data were available in 530, 270, 117 and 40 of the
890 patients, respectively. PD solutions with neutral calcium content
(1.25–1.35 mmol/l) were used in 65%, high calcium (1.75 mmol/l) in
30% and low calcium (o1.25 mmol/l) in 5% of patients.
PTH assays
Second generation PTH assays were used in 58 of 61 centers.
These included direct chemiluminescence assays (DPC Biermann/
SIEMENS Medical Solutions Diagnostics, Bad Nauheim, Germany,
Beckman Access, Beckman Coulter, Brea, CA, USA, Diasorin Liaison
N-tact PTH, Diasorin, Saluggia, Italy) in 43.3%, the Roche
(Hoffmann-La Roche, Basel, Switzerland) Elecsys iPTH electro-
chemiluminescence assay in 27.2%, immunoradiometric assays
(CIS-Bio ELSA PTH, CIS-bio, Berlin, Germany, Biosource Europe
iPTH-120min-IRMA, DIAsource ImmunoAssays, Nivelles, Belgium)
in 21.9% and ELISAs (Biomerica ELISA iPTH, Biomerica, Irvine,
CA, USA, Tosoh Intact PTH, Tosoh Bioscience, South San Francisco,
CA, USA) in 2.4% of measurements. Two centers used the Nichols’
Advantage third generation bioIntact PTH assay, and one center
the Scantibodies third generation whole-PTH assay). To eliminate
assay-related systematic differences in PTH concentrations, the
reported PTH values were normalized by applying the assay-specific
conversion factors suggested by Souberbielle et al.23,24 Reported
PTH concentrations were divided by 0.9 for the Liaison N-tact
PTH, by 0.7 for the bioIntact PTH Advantage and by 0.55 for
the Scantibodies whole-PTH assay. These conversions applied to
10.1% of all PTH measurements in the study.
Statistics
Time integrated means were calculated for the biochemical
parameters according to individual observation times. Height was
normalized to SDSs, using the World Health Organization 2006
normative values for children up to age 5 years and the National
Center for Health Statistics 2000 reference charts for older
children.25,26 The annualized change in height SDS was calculated
in all children with at least 6 months follow-up.
Data was checked for normal distribution by the Kolmogor-
ov–Smirnoff test. Differences in group means (log-transformed in
case of non-Gaussian distribution) were assessed by Student’s t test
for two-group comparisons, and by analysis of variance followed by
Student’s Newman–Keuls testing for multiple comparisons. Differ-
ences in proportions were assessed by w2 testing. Stepwise multiple
linear regression and logistic regression were used for multivariate
data analysis as appropriate. Receiver operating characteristic
analysis was performed to identify the PTH target range associated
with minimal CKD–MBD manifestations.
All data analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA).
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Appendix
The following Principal Investigators are contributing to the
International Pediatric Peritoneal Dialysis Network Registry:
Argentina: E Sojo, Hospital de Pediatria Garrahan,
Buenos Aires; PA Coccia, Hospital Italiano de Buenos Aires;
A Suarez, Hospital de Nin˜os Sor. Maria Ludovica La Plata;
PG Valles, Hospital Pediatrico Humberto Notti, Mendoza, R
Salim, Rennius SA Salta. Belgium: K van Hoeck, University
Hospital Antwerp, Edegem. Brazil: V Koch, Instituto da
Crianc¸a–Hospital das Clinicas FMUSP, Sao Paulo. Canada: J
Feber, Children’s Hospital of Eastern Ontario, Ottawa; DA
Geary, Hospital for Sick Children, Toronto; C White, BC
Children’s Hospital, Vancouver. Chile: M Valenzuela, Hospi-
tal Guillermo Grant Benavente, Concepcion; J Villagra,
Hospital Base, Osorno; F Cano, Hospital Luis Calvo
Mackenna,Santiago, MA Contreras, Roberto del Rio Hospi-
tal, Santiago; A Vogel, Pontivicia Universidad Catolica de
Chile, Santiago; P Zambrano, Hospital Dr Gonzales Cortes,
Santiago, P Berrocal Hospital Sotero del Rio, Santiago.
China: MC Chiu, Department of Pediatric and Adolescent
Medicine, Hong Kong, H Xu, Children’s Hospital of Fudan
University, Shanghai. Czech Republic: K Vondrak, University
Hospital Motol, Prague. Finland: K Ro¨nnholm, Hospital for
Children and Adolescents, Helsinki; France: B Ranchin,
Hoˆpital Femme Me`re Enfant, Lyon; T Ulinski, Armand
Trousseau Hospital, Paris; M Fischbach, Children’s Dialysis
Center, Strasbourg. Germany: R Bu¨scher, Children’s Hospital
Essen; M Kemper, University Medical Center, Hamburg; L Pape,
Medical School, Hannover; F Schaefer, D Borzych, Center for
Pediatrics and Adolescent Medicine, Heidelberg; U John,
Kidney Center for Children and Adolescents, Jena; G Klaus,
University Hospital, Marburg; D Haffner, University Chil-
dren’s Hospital, Rostock. Greece: F Papachristou, Aristoteles
University, Thessaloniki. India: A Bagga, All India Institute of
Medical Sciences, New Delhi; M Kanitkar, Armed Forces
Medical College, Pune. Italy: E Verrina, G Gaslini Institute,
Genova; A Edefonti, Fondazione Ospedale Maggiore Policli-
nico, Milano; G Leozappa, Dip. Nefrologia-Urologia, Rome.
Israel: D Landau, Soroka Medical Center, Beer-Sheva. Korea:
IS Ha, Dialysis Center for Children and Adolescents, Seoul;
KH Paik, Samsung Medical Center, Seoul. Macedonia: E
Sahpazova, Pediatric Clinic, Skopje. Netherlands: JW Grooth-
off, Academic Medical Center, Amsterdam. Nicaragua: Y
Silva, Hospital Infantil de Nicaragua, Managua. Poland: AM
Zurowska, D Borzych, Medical University, Gdansk; D
Drozdz, University Children’s Hospital, Krakow; M Lipka,
Children’s Memorial Health Institute, Warsaw; M Sczepans-
ka, Dialysis Division for Children, Zabrze. Romania: O
Brumariu, St Maria Children’s Hospital, Iasi. Singapore: HK
Yap, Shaw-NKF-NUH Children’s Kidney Center. Spain: G
Ariceta, Hospital de Cruces, Baracaldo. Turkey: F Ozaltin,
Hacettepe University, Ankara; S Bakkaloglu, Gazi University,
Ankara; I Bilge, Department of Pediatric Nephrology, C¸apa-
Istanbul; E Serdaroglu, Dr Behcet Children Research and
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Educational Hospital, Izmir; A Bal, Tepecik Children and
Research Hospital, Izmir; S Mir, Ege University Faculty of
Medicine, Izmir-Bornova. United Kingdom: L Rees, Great
Ormond Street Hospital, London. AR Watson, Children and
Young People’s Kidney Unit, Notthingham. Uruguay: J
Gru¨nberg, SE.N.NI.AD, Montevideo. USA: L Greenbaum,
Children’s Healthcare Pediatric Dialysis Unit, Atlanta; A Neu,
Johns Hopkins Hospital, Baltimore; D Askenazi, Children’s
Hospital of Alabama, Birmingham; D Gipson, University of
North Carolina, Chapel Hill; H Patel, Cildren’s Hospital,
Columbus; S Pottoore, Children’s Medical Center, Dallas; V
Dharnidharka, Division of Pediatric Nephrology, Gainesville;
T Bunchman, Helen DeVos Children’s Hospital, Grand Rapids;
A Chua, Texas Children’s Hospital, Houston; BA Warady,
Children’s Mercy Hospital, Kansas City; J Zaritsky, UCLA
Medical Center, Los Angeles.
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